The US presidential election process has crystallized into a rematch between Joe Biden and Donald Trump and so drug pricing reform will be an ongoing concern for industry.
Key Takeaways
-
President Joe Biden's ability to take on major new drug pricing reforms in a second term will depend on the makeup of Congress.
The biopharma industry has a pretty good idea of what drug pricing reform policies President Joe Biden will pursue if...







